Medical Pharmacology: Antiviral Drug Practice Questions`

Medical Pharmacology: Antiviral Drug Practice Questions

Atazanavir (Reyataz)

Click on the correct answer.

Atazanavir (Reyataz):
1. Azapeptide protease inhibitor
2. Exhibits activity against HIV-1 and HIV-2
3. Both
4. Neither
Atazanavir (Reyataz) is also:
1. Available in combination with cobicistat
2. Available in combination with ritonavir
3. Both
4. Neither
Atazanavir (+/- ritonavir)
1. Approved for treating adults
2. Approved also for treating pediatric patients >3 months of age and weighing at minimum 5 kg.
3. Both
4. Neither
With respect to "high-level" resistance: if 5 or more mutations are present in an HIV strain, the likelihood of resistance to the antiviral effects of as atazanavir is elevated.
1. True
2. False
Atazanavir (Reyataz):
1. Suitable for once-a-day dosing
2. Should be taken with food (meals)
3. Both
4. Neither
Atazanavir pharmacokinetics:
1. Half-life of the drug and the plasma is about 6-7 hours which increases to 8-9 hours if the drug is coadministered with ritonovir.
2. Primary elimination route is through biliary excretion.
3. Both
4. Neither
Atazanavir + ritonavir (boosted atazanivir) is one of the recommended formulations of protease inhibitors for treating pregnant women.
1. True
2. False
The most common adverse effect as a result of atazanavir administration is gastrointestinal symptoms.
1. True
2. False
With atazanavir administration, mild skin rash occurs in about 20% of patients.
1. True
2. False
Atazanavir (Reyataz): Hyperbilirubinemia (indirect) with jaundice may occur in about 10% of patients.
1. True
2. False
Given that atazanavir (Reyataz) is an inhibitor of CYP3A4, CYP2C9, and UGT1A1, enzymes that metabolize many other drugs, there is a high likelihood of drug-drug interactions.
1. True
2. False

Previous Antiviral Pharmacology Practice Question Set

Next Antiviral Pharmacology Practice Question Set

If you wish to return to the Table of Contents in ENGLISH, press the RETURN button above.

Otherwise, if the text is NOT displayed in English and you are ready to leave this page, Press here to return to the Table of Contents

Source Material:

Acosta EP Chapter 62 Antiviral Agents (Nonretroviral) in Goodman & Gilman's: The Pharmcological Basis of Therapeutics, 14e, (Brunton LL Knollmann BC eds) McGraw-Hill Education, 2023.

Safrin S Chapter 49 Antiviral Agents in Basic & Clinical Pharmacology (Katzung BG, Editor; Vanderah TW, Associate editor) 15e McGraw Hill 2021.

Li JZ Coen DM Chapter 38 Pharmacology of Viral Infections in Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy 4e (Golan DE Armstong EJ Armstrong AW, eds) Wolters Kluwer 2017.

Waller DB Sampson AP Section 11 Chemotherapy in Medical Pharmacology & Therapeutics Elsevier 2018.

Burchum JR Rosenthal LD Chapter 97 Antiviral Agents I: Drugs for Non-HIV Viral Infections in Lehne's Pharmacology for Nursing Care Elsevier 2022.

Waller DB Sampson AP Section 11: Chapter 51 Chemotherapy of infections in Medical Pharmacology & Therapeutics Elsevier 2018.

Benavides S Bahal O'Mara N Nahata MC Chapter 79 Viral Infections in Applied Therapeutics: The Clinical Use of Drugs (Zeind C, Carvalho MG Cheng JW Zaiken K Lapointe T, eds) Wolters Kluwer, 2024.

Davanathan AS Symonds AE Adams JL Cottrell ML Chapter 76 Pharmacotherapy of Human Immunodeficiency Virus Infection in Applied Therapeutics: The Clinical Use of Drugs (Zeind C, Carvalho MG Cheng JW Zaiken K Lapointe T, eds) Wolters Kluwer, 2024.

Flexner CW Chapter 64 Antiretroviral Agents and Treatment of HIV Infection in Goodman & Gilman's: The Pharmcological Basis of Therapeutics, 14e, (Brunton LL Knollmann BC eds) McGraw-Hill Education, 2023.